In line with previous research, a new study in mice demonstrates that B cells can be engineered to ward off infections, this time against respiratory syncytial virus (RSV).

An early-stage clinical study finds that none of the 25 patients treated developed neurotoxicity or cytokine release syndrome, common hazards of the cancer immunotherapy.

Researchers report they’ve found a way to restore immune function in infants with one form of “bubble boy disease.”

Type I interferon organizes several immune mechanisms to suppress B cell responses to a chronic viral infection.

Gut bacteria in mice spur regulatory B cells to differentiate and release an anti-inflammatory cytokine.

B cells have commandeered ancient viral sequences in the genome to transmit antigen signals.

T-cells engineered to attack B-cells sent adults’ acute leukemia into remission.

Editor’s Choice in Immunology